Video Interview: Q BioMed Accelerates Advances In Vascular Therapeutics
This article was originally published in Scrip
Executive Summary
Ensuring that all the necessary resources are in place to build a sustainable business is a key challenge for most entrepreneurs. They need access to capital and expertise without having to give it away cheaply. Q BioMed Inc CEO Denis Corin explains to Mike Ward, global director of content for Informa's pharma insight products, how his biomedical acceleration and development company is providing target companies and assets access to strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential.
You may also be interested in...
Q BioMed Plans To Accelerate Up To Four More Assets
Established Jun 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add additional assets to its portfolio. Company founder and CEO Denis Corin describes the progress Q BioMed has made with its first two assets and outlines his ambition to expand further in the coming two to three years.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.